Global pharma shifting high-value clinical research work to India: Parexel
Parexel reports India is becoming a key global hub for high-value clinical research, with over 6,000 employees (25-30% of its workforce) handling core functions like AI-driven pharmacovigilance and regulatory affairs, while multinational pharma firms relocate decision-making roles from the US and Europe. The shift is driven by India’s maturing regulatory standards, digital trial adoption, and growing biotech focus, though patient participation remains low at 3% of global trials despite its population size.
Parexel, a global clinical research services firm, states India is transitioning from a low-cost outsourcing hub to a strategic center for innovation and decision-making in pharmaceutical development. The country now hosts over 6,000 Parexel employees—about 25-30% of its 24,000-strong global workforce—handling core functions such as clinical operations, pharmacovigilance, regulatory affairs, and AI-enabled automation. Sanjay Vyas, president and managing director of Parexel, highlights that multinational pharma companies are relocating critical roles from the US and Europe to India, where operations now resemble standalone clinical research organizations. India’s regulatory framework is aligning with global standards like those of the US FDA, UK MHRA, and European EMA, supporting decentralized and digital clinical trials. Parexel has expanded its AI capabilities through acquisitions like Vitrana and partnerships with firms such as WeveBio and Paradigm to streamline drug submissions and patient recruitment. The country’s large disease burden and expanding healthcare infrastructure are further driving global interest, though clinical trial participation remains limited to 3% of worldwide trials. Parexel projects its India workforce could reach 8,000 within three years, fueled by rising investments in biotech and advanced therapies like oncology and gene therapy. Challenges remain, including low awareness of clinical trials and underdeveloped infrastructure outside major cities. Vyas emphasizes the need for broader outreach and Tier-II/Tier-III city expansion to unlock India’s full potential in the sector.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.